KEY STUDY PERSONNEL Duane A. Mitchell, M.D., Ph.D. (Principal Investigator) is Associate Professor of Neurosurgery, Neuroscience, Pathology, and Immunology, Co- Director of the Preston A. Wells, Jr. Center for Brain Tumor Therapy, and Director of the University of Florida Brain Tumor Immunotherapy Program. Dr. Mitchell has considerable translational research experience involving the immunologic treatment of cancer. Dr. Mitchell is a graduate of the prestigious NIH -sponsored Medical Scientist Training Program (MD/PhD Program) and received his Ph.D. under the guidance of Dr. Eli Gilboa, a world -renowned tumor immunologist and pioneer of the RNA transfected DC platform that will serve as the antigen presentation platform in this investigation. He has devoted his research efforts on the development of immunotherapeutic approaches to the tr eatment of malignant brain tumors, and has served as PI on seven FDA and IRB approved Phase I/II clinical trials investigating immunotherapy in patients with malignant brain tumors. He is the Chair of the Immunotherapy Working Group for the NCI Pediatric Brain Tumor Consortium and a panel member of the Immunotherapy Working Group for the NCI Brain Malignancy Steering Committee. The study outlined in this proposal will be conducted under FDA IND -BB-14058 covering the use of adoptive T cell therapy and ampli fied total tumor RNA - pulsed DCs in pediatric patients with recurrent MB/PNETs. He will be responsible for supervising all aspects of the study; including writing and disseminating all study results and reports.